Blue Jet Healthcare Ltd.

“Blue Jet Healthcare is a structurally sound, high-ROIC specialty chemistry business with a defensible regulatory moat in iodinated contrast media intermediates, clean balance sheet, and secular CT imaging tailwinds — but it is constrained by a narrow TAM, extreme customer concentration (GE Healthcare ~40-45% of revenue), and a limited reinvestment runway that collectively cap long-term compounding potential. At 26x forward earnings, expected 5-year returns of ~9-10% CAGR fall short of India's equity cost of capital, leaving no margin of safety. The primary permanent-impairment risk — a major customer sponsoring an alternative intermediate supplier — is non-trivial at 15-25% probability over five years. The right action is to track for a better entry (INR 320-360) rather than commit capital today.”